Mucopolisaccharidosis type I (MPS I), produced by a deficiency of ␣-l-iduronidase (EC 3.2.1.76) activity, can manifest three major clinical phenotypes: Hurler, Scheie, and Hurler-Scheie syndromes. The clinical phenotypes cannot be differentiated by routine biochemical diagnostic procedures. Mutation analysis allows the classification of some patients, but in most cases assignment to an MPS I type can be made only on the basis of clinical criteria (1 ) .
In the last few years treatment of MPS I became possible by bone marrow transplantation (2 ) , enzyme replacement therapy (3 ), and gene transfer or gene modification (4 ) . The effectiveness of these therapies, particularly for MPS involving the central nervous system, may rely heavily on early diagnosis of the disorder. An additional consideration critical to bone marrow transplantation is that early diagnosis of the patient will allow clinicians to take advantage of the period of natural suppression of the immune system of the neonate to maximize the chances of a successful engraftment. Except for those cases with a family history of the disease, presymptomatic detection of MPS I can be achieved only by newborn screening (5 ) . In any case, a simple technique suitable for dried blood spots on filter paper (DBFP) is needed.
The most widely used specimens for the diagnosis of iduronidase deficiency have been homogenates of cultured fibroblasts or leukocytes. Analysis of iduronidase in leukocytes is preferred because it avoids time-consuming and costly tissue culture. However, isolation of leukocytes from venous blood is also time-consuming. Additionally, transport of these samples from one city or country to another is difficult.
Several microtests for the assay of iduronidase in plasma and/or leukocytes have been published (6, 7 ) , but these methods have not been applied to DBFP. We describe here an adaptation of the fluorescence method (8 ) used for leukocyte assay of ␣-l-iduronidase activity to DBFP. 4-Methylumbelliferyl-␣-l-iduronide, 4-methylumbelliferone, and d-saccharic acid-1,4-lactone were purchased from Sigma. All other chemicals were of highpurity grade.
Blood samples obtained from 40 healthy individuals 18 -37 years of age were spotted on filter paper (Schleicher and Schuell no. 903) and allowed to dry 4 h at room temperature. Filter papers were stored at 4°C in plastic bags until analysis. The assays were performed not more than 72 h after blood sampling. Twenty-five DBFP samples from our newborn screening program collected on the 3rd to 7th day postpartum were also analyzed. DBFP samples from five cases of MPS I type Scheie (age range, 10 -34 years), four cases of MPS I type Hurler (age range, 2-4 years), and four obligate carriers were obtained after informed consent of the patients or families and processed in the same way. Diagnosis of MPS in these patients was established by clinical and standard biochemical procedures.
To duplicate disposable 1-mL test tubes containing a 3-mm diameter circle paper (5.5 L of blood) obtained with a standard paper punch we added 40 L of 50 mmol/L formate buffer (pH 2.8) containing 0.3 g of d-saccharic acid-1,4-lactone as elution liquid and 20 L of 2 mmol/L 4-methyhylumbelliferyl-␣-l-iduronide in distilled water as substrate. After vortex-mixing for 1 min, the tubes were incubated for 20 h at 37°C in a shaking water bath. The tubes were then placed on ice, and 300 L of glycine-carbonate buffer (0.085 mol/L, pH 10.5) was added to stop the reaction. The tubes were vortexmixed and allowed to stand for 30 min at room temperature.
The filter paper need not be removed during the analysis. Assays were performed in duplicate. One blank tube was run for each sample of the assay. Blanks were prepared by adding 300 L of glycine-carbonate buffer (0.085 mol/L, pH 10.5) to a mixture of the paper punch in the elution liquid and the substrate, which had been incubated separately. Fluorescence (excitation, 365 nm; emission, 450 nm) of the enzyme product 4-methylumbelliferone was measured on a Farrand fluorometer Model RF-2 (Farrand Optical Inc.). The fluorescence readings were corrected for blanks, and the results were compared with the fluorescence from a 4-methylumbelliferone calibrator. Enzymatic activities were expressed as micromoles of substrate hydrolyzed per liter of blood per 20 h. Different assays were performed to establish the appropriate elution liquid, buffer, pH, and substrate concentrations (data not shown). Assay imprecision was calculated by replicate analysis of the DBFP from a health control (␣-iduronidase activity, 61.1 mol ⅐ L Ϫ1 blood ⅐ 20 h Ϫ1 ) and from an obligate carrier (␣-iduronidase activity, 33.5 mol ⅐ L Ϫ1 blood ⅐ 20 h Ϫ1 ). The within-assay CVs were 7.7% and 8.4% (n ϭ 10), respectively. The interassay CVs for both DBFP samples studied on five different occasions within 1 month were 7.1% and 9.1%, respectively.
Blood from a healthy adult (␣-iduronidase activity, 61.1 mol ⅐ L Ϫ1 blood ⅐ 20 h Ϫ1 ) was mixed in equal proportions with blood from a Hurler patient (␣-l-iduronidase activity, 0 mol ⅐ L Ϫ1 blood ⅐ 20 h Ϫ1 ); the resulting activity was 32.9 mol ⅐ L Ϫ1 blood ⅐ 20 h Ϫ1 . The effect of variable incubation times on the activities of iduronidase is shown in Fig. 1 .
There were no significant changes in enzyme activity of DBFP samples after storage for 21 days at 4°C or Ϫ20°C (n ϭ 5). When samples from a control, an obligate carrier, and a Hurler patient were stored at room temperature (26°C) for the same period, the iduronidase activity decreased from of 128, 41, and 2.2 mol ⅐ L Ϫ1 blood ⅐ 20 h Ϫ1 to 85.7, 29.1, and 1.7 mol ⅐ L Ϫ1 blood ⅐ 20 h Ϫ1 , respectively.
The iduronidase activities of healthy individuals, newborn controls, obligate carriers, and MPS I patients are shown in Table 1 . There was no overlap among the results of MPS I patients and carriers or controls. DBFP samples from MPS I patients showed iduronidase activities Յ8% and 6% of the mean values of adult and newborn controls, respectively. No differences were found between the Hurler and Scheie patients. In leukocytes, the absolute iduronidase activity varies with assay conditions, but a finding of Ͻ10% of the mean activity in healthy subjects is accepted as diagnostic of MPS I (8 ) . In our DBFP assay, the obligate carriers overlapped with the healthy adult range.
The present methodology is easier, faster, and less expensive than the leukocyte assay. A drop of blood obtained through heel prick is sufficient to perform the assay in duplicate plus one blank. Sample transportation is safe. Minimal activity loss occurs during storage at room temperature up to 20 days. This fact does not modify the recognition of MPS I patients and controls, and it usually is enough time to mail the DBFP sample to a specialized laboratory for analysis. Our results suggest that this method allows the diagnosis of MPS I in DBFP samples. However, it will be necessary to study a larger number of patients and carriers to validate this methodology.
The possibility of an early diagnosis and the treatment of presymptomatic MPS I patients is desirable; the use of this methodology for a pilot newborn-screening program thus appears as a reasonable approach. Such a pilot study will eventually define whether massive newborn screening is indicated. In that case, microplate adaptation and automation of the method could be easy.
The iduronidase activity test in DBFP samples appears to be a reasonable approach for the initial diagnosis of MPS I. Because clinical differentiation among different types of MPS is difficult, especially with Maroteaux-Lamy syndrome and ␤-glucuronidase deficiency, we are working on the development of similar methods using DBFP samples for the diagnosis of other MPS disorders. In abnormal cases, a blood sample for leukocyte isolation or a fibroblast skin culture can be requested for further characterization of the biochemical and molecular phenotype of the disorder. 
